Healthcare of Ontario Pension Plan Trust Fund Sells 738,026 Shares of Urogen Pharma $URGN

Healthcare of Ontario Pension Plan Trust Fund cut its holdings in Urogen Pharma (NASDAQ:URGN - Free Report) by 65.6% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 387,074 shares of the company's stock after selling 738,026 shares during the period. Healthcare of Ontario Pension Plan Trust Fund owned 0.79% of Urogen Pharma worth $6,960,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in URGN. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Urogen Pharma by 27.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company's stock valued at $53,000 after buying an additional 486 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Urogen Pharma by 7.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company's stock worth $258,000 after acquiring an additional 1,653 shares during the last quarter. Main Street Financial Solutions LLC boosted its position in shares of Urogen Pharma by 8.2% during the second quarter. Main Street Financial Solutions LLC now owns 25,968 shares of the company's stock worth $356,000 after acquiring an additional 1,968 shares during the last quarter. Barclays PLC grew its stake in Urogen Pharma by 3.8% during the fourth quarter. Barclays PLC now owns 57,744 shares of the company's stock valued at $1,352,000 after acquiring an additional 2,125 shares in the last quarter. Finally, Osaic Holdings Inc. grew its stake in Urogen Pharma by 491.2% during the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company's stock valued at $50,000 after acquiring an additional 3,070 shares in the last quarter. 91.29% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Urogen Pharma news, insider Mark Schoenberg sold 10,000 shares of the business's stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $40.00, for a total transaction of $400,000.00. Following the transaction, the insider owned 119,763 shares in the company, valued at $4,790,520. The trade was a 7.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 25,222 shares of company stock worth $892,661 over the last ninety days. 4.80% of the stock is owned by insiders.

Urogen Pharma Price Performance

NASDAQ:URGN opened at $40.45 on Thursday. The firm has a market capitalization of $1.97 billion, a price-to-earnings ratio of -14.71 and a beta of 1.56. The business has a 50 day simple moving average of $34.57 and a 200-day simple moving average of $26.07. Urogen Pharma has a 1 year low of $15.86 and a 1 year high of $43.93.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.01. The company had revenue of $50.96 million for the quarter, compared to the consensus estimate of $44.83 million. As a group, analysts expect that Urogen Pharma will post -0.76 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have commented on URGN. The Goldman Sachs Group reiterated a "neutral" rating and issued a $44.00 price target on shares of Urogen Pharma in a research note on Wednesday, July 15th. Oppenheimer raised their price objective on Urogen Pharma from $40.00 to $50.00 and gave the company an "outperform" rating in a research report on Thursday, July 16th. LADENBURG THALM/SH SH started coverage on Urogen Pharma in a report on Monday, May 11th. They issued a "buy" rating and a $43.00 target price on the stock. Guggenheim boosted their target price on Urogen Pharma from $32.00 to $42.00 and gave the stock a "buy" rating in a research report on Tuesday, July 21st. Finally, Jefferies Financial Group raised Urogen Pharma to a "strong-buy" rating in a research note on Friday, April 24th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $41.62.

Urogen Pharma Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra'anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company's lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.